Yafeng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yafeng Zhou has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Yufeng Jiang
Department of Cardiology, Suzhou Dushu Lake Hospital, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou, Jiangsu, 215000, Republic of China
11 shared publications- Yufeng Jiang
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China
11 shared publications Min Chen
Soochow Univ, Affiliated Hosp 1, Dept Cardiol, 188 Shizi Rd, Suzhou 215006, Jiangsu, Peoples R China
9 shared publicationsQing Rui
Department of Cardiology, the First Affiliated Hospital of Soochow University
9 shared publicationsNan-Nan Zhang
Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, P.R. China
8 shared publicationsHua-Jia Yang
Department of Cardiology, the First Affiliated Hospital of Soochow University
7 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
Epigenetic silencing of FCGR2A by promoter hypermethylation exacerbates cardiac remodeling in post-myocardial infarction heart failure
- 29 September 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
Open AccessEpigenetic silencing of FCGR2A by promoter hypermethylation exacerbates cardiac remodeling in post-myocardial infarction heart failure
- Open Access
- 17 July 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Synergistic effect of AIP and cystatin C: a study on cardiovascular risk prediction in populations with different glycemic statuses
Cardiovascular disease (CVD) poses a major global health burden. The Atherogenic Index of Plasma (AIP) and Cystatin C are novel biomarkers reflecting lipid metabolism disorders and renal/micro-inflammatory status, respectively. Their combined indicator (AIP-Cys, the product of AIP × Cystatin C) may provide improved predictive value beyond either marker alone. This study aimed to investigate the predictive role of AIP-Cys for the risk of incident CVD across different glycemic statuses: normal glucose regulation (NGR), pre-diabetes (preDM), and diabetes mellitus (DM). This study was based on the prospective China Health and Retirement Longitudinal Study (CHARLS) cohort. A total of 6,035 participants aged ≥ 45 years without a history of CVD at baseline (2011) were included. The primary exposure was baseline AIP-Cys (the product of AIP × Cystatin C), and the outcome was the first self-reported incident heart disease or stroke event during follow-up (until 2020). Glycemic status was defined based on fasting plasma glucose and glycated hemoglobin levels. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs). Restricted cubic splines and piecewise linear models were applied to analyze nonlinear relationships. Mediation and sensitivity analyses were conducted to verify the robustness of the results. During a median follow-up of 9.0 years, 651 incident CVD cases occurred. In the fully adjusted model, AIP-Cys was independently associated with CVD risk in the overall (HR per unit increase: 1.34; 95% CI: 1.06-1.69), NGR (HR: 1.60; 95% CI: 1.13-2.26), and preDM (HR: 1.32; 95% CI: 1.02-1.70) populations, but not in the DM population. RCS analysis revealed a significant nonlinear relationship in the NGR and preDM groups (P for nonlinearity < 0.05). Piecewise regression identified inflection points (0.47 for NGR; 0.37 for preDM), below which risk increased sharply. Quartile analysis showed the highest risk in Q3 rather than Q4, suggesting a saturation effect. Mediation analysis indicated that systolic blood pressure partially mediated this association (mediating proportion: 14.6% in overall population). The predictive performance of AIP-Cys was modest for short-term risk (1-year AUC: 0.64-0.67) but limited for long-term prediction. The composite indicator AIP-Cys, derived from AIP and Cystatin C, is an independent risk factor for incident CVD in individuals with NGR and preDM. The association exhibits a nonlinear threshold pattern. However, its predictive value is limited in the DM population, and its long-term predictive performance is modest. Additionally, the self-reported nature of cardiovascular outcomes represents a limitation that should be considered when interpreting these findings. By integrating lipid metabolism and renal/inflammatory pathways, this indicator offers a novel biomarker-based approach for early cardiovascular risk identification in the pre-diabetes stage. Future research should further explore its potential for clinical translation and intervention.
- 17 July 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Open AccessSynergistic effect of AIP and cystatin C: a study on cardiovascular risk prediction in populations with different glycemic statuses
Cardiovascular disease (CVD) poses a major global health burden. The Atherogenic Index of Plasma (AIP) and Cystatin C are novel biomarkers reflecting lipid metabolism disorders and renal/micro-inflammatory status, respectively. Their combined indicator (AIP-Cys, the product of AIP × Cystatin C) may provide improved predictive value beyond either marker alone. This study aimed to investigate the predictive role of AIP-Cys for the risk of incident CVD across different glycemic statuses: normal glucose regulation (NGR), pre-diabetes (preDM), and diabetes mellitus (DM). This study was based on the prospective China Health and Retirement Longitudinal Study (CHARLS) cohort. A total of 6,035 participants aged ≥ 45 years without a history of CVD at baseline (2011) were included. The primary exposure was baseline AIP-Cys (the product of AIP × Cystatin C), and the outcome was the first self-reported incident heart disease or stroke event during follow-up (until 2020). Glycemic status was defined based on fasting plasma glucose and glycated hemoglobin levels. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs). Restricted cubic splines and piecewise linear models were applied to analyze nonlinear relationships. Mediation and sensitivity analyses were conducted to verify the robustness of the results. During a median follow-up of 9.0 years, 651 incident CVD cases occurred. In the fully adjusted model, AIP-Cys was independently associated with CVD risk in the overall (HR per unit increase: 1.34; 95% CI: 1.06-1.69), NGR (HR: 1.60; 95% CI: 1.13-2.26), and preDM (HR: 1.32; 95% CI: 1.02-1.70) populations, but not in the DM population. RCS analysis revealed a significant nonlinear relationship in the NGR and preDM groups (P for nonlinearity < 0.05). Piecewise regression identified inflection points (0.47 for NGR; 0.37 for preDM), below which risk increased sharply. Quartile analysis showed the highest risk in Q3 rather than Q4, suggesting a saturation effect. Mediation analysis indicated that systolic blood pressure partially mediated this association (mediating proportion: 14.6% in overall population). The predictive performance of AIP-Cys was modest for short-term risk (1-year AUC: 0.64-0.67) but limited for long-term prediction. The composite indicator AIP-Cys, derived from AIP and Cystatin C, is an independent risk factor for incident CVD in individuals with NGR and preDM. The association exhibits a nonlinear threshold pattern. However, its predictive value is limited in the DM population, and its long-term predictive performance is modest. Additionally, the self-reported nature of cardiovascular outcomes represents a limitation that should be considered when interpreting these findings. By integrating lipid metabolism and renal/inflammatory pathways, this indicator offers a novel biomarker-based approach for early cardiovascular risk identification in the pre-diabetes stage. Future research should further explore its potential for clinical translation and intervention.
- Open Access
- 12 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis
Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant efficacy in the management of myocardial infarction (MI). However, its direct cytoprotective effects on cardiomyocytes and vascular endothelial cells remain unclear. This study was performed to evaluate the cardioprotective and vasoprotective effects of finerenone following MI and to elucidate its underlying mechanisms. An in vitro oxygen-glucose deprivation (OGD) model was utilized to mimic ischemic conditions. H9C2 rat cardiomyoblasts and human umbilical vein endothelial cells were employed to assess the protective effects of finerenone. For in vivo assessment, a murine model of MI was established and treated with oral finerenone for 28 consecutive days. Cardioprotective outcomes were evaluated through electrocardiography, echocardiography, serum biochemical markers, histopathological analyses, and protein expression profiling. Finerenone significantly improved the viability of cardiomyocytes and endothelial cells subjected to OGD, reduced autophagosome accumulation by enhancing autophagosome degradation, inhibited apoptosis, and promoted endothelial cell migration and tube formation capacity. In vivo, finerenone improved cardiac function parameters, reduced serum levels of myocardial enzyme profiles and brain natriuretic peptides, decreased myocardial infarct size, enhanced left ventricular function, and alleviated myocardial inflammation, fibrosis and apoptosis. Mechanistically, finerenone downregulated the expression of ATG5 and apoptosis-related molecules in myocardial tissue, while enhancing the expression of Ang and VEGF involved in angiogenesis. Finerenone confers significant cardioprotection by inhibiting autophagy, apoptosis, and enhancing angiogenesis in both cardiomyocytes and vascular endothelial cells. These findings provide experimental evidence for the clinical utility of finerenone for secondary prevention after MI.
- 12 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessFinerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis
Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant efficacy in the management of myocardial infarction (MI). However, its direct cytoprotective effects on cardiomyocytes and vascular endothelial cells remain unclear. This study was performed to evaluate the cardioprotective and vasoprotective effects of finerenone following MI and to elucidate its underlying mechanisms. An in vitro oxygen-glucose deprivation (OGD) model was utilized to mimic ischemic conditions. H9C2 rat cardiomyoblasts and human umbilical vein endothelial cells were employed to assess the protective effects of finerenone. For in vivo assessment, a murine model of MI was established and treated with oral finerenone for 28 consecutive days. Cardioprotective outcomes were evaluated through electrocardiography, echocardiography, serum biochemical markers, histopathological analyses, and protein expression profiling. Finerenone significantly improved the viability of cardiomyocytes and endothelial cells subjected to OGD, reduced autophagosome accumulation by enhancing autophagosome degradation, inhibited apoptosis, and promoted endothelial cell migration and tube formation capacity. In vivo, finerenone improved cardiac function parameters, reduced serum levels of myocardial enzyme profiles and brain natriuretic peptides, decreased myocardial infarct size, enhanced left ventricular function, and alleviated myocardial inflammation, fibrosis and apoptosis. Mechanistically, finerenone downregulated the expression of ATG5 and apoptosis-related molecules in myocardial tissue, while enhancing the expression of Ang and VEGF involved in angiogenesis. Finerenone confers significant cardioprotection by inhibiting autophagy, apoptosis, and enhancing angiogenesis in both cardiomyocytes and vascular endothelial cells. These findings provide experimental evidence for the clinical utility of finerenone for secondary prevention after MI.
- Open Access
- 22 January 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2610849
Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation
The PCSK9-LDLR interaction, driving elevated LDL-C, is a key driver of ASCVD pathogenesis. Identifying peptides disrupting this interaction offers an alternative ASCVD therapy. Herein, via structure-based virtual screening with Pep2-8 as a control, we identified TPP-4, a high-affinity peptide inhibitor targeting PCSK9. Compared to Pep2-8, TPP-4 showed lower binding free energy (approximately -9.8 kcal/mol) and Kd values (Kd = 0.08 ± 0.01 μM), interacting with PCSK9's LDLR-binding domain through multiple interactions. CD spectroscopy also provided indirect evidence for these key interactions. Additionally, it stably bound to the LDLR binding domain of PCSK9 during 100 ns MD simulations. It showed good serum stability, negligible HepG2 cytotoxicity, and restored surface LDLR (EC50 = 1.12 ± 0.05 μM). In mice, TPP-4 upregulated hepatic LDLR and reduced plasma total cholesterol levels. In conclusion, these data demonstrate that TPP-4 could be a high-affinity and potent candidate peptide for ASCVD treatment.
- 22 January 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2610849
Open AccessIdentification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation
The PCSK9-LDLR interaction, driving elevated LDL-C, is a key driver of ASCVD pathogenesis. Identifying peptides disrupting this interaction offers an alternative ASCVD therapy. Herein, via structure-based virtual screening with Pep2-8 as a control, we identified TPP-4, a high-affinity peptide inhibitor targeting PCSK9. Compared to Pep2-8, TPP-4 showed lower binding free energy (approximately -9.8 kcal/mol) and Kd values (Kd = 0.08 ± 0.01 μM), interacting with PCSK9's LDLR-binding domain through multiple interactions. CD spectroscopy also provided indirect evidence for these key interactions. Additionally, it stably bound to the LDLR binding domain of PCSK9 during 100 ns MD simulations. It showed good serum stability, negligible HepG2 cytotoxicity, and restored surface LDLR (EC50 = 1.12 ± 0.05 μM). In mice, TPP-4 upregulated hepatic LDLR and reduced plasma total cholesterol levels. In conclusion, these data demonstrate that TPP-4 could be a high-affinity and potent candidate peptide for ASCVD treatment.
- Open Access
- 7 August 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
A predictive nomogram for intramyocardial hemorrhage in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention based on coronary angiography-derived index of microcirculatory resistance
Intramyocardial hemorrhage (IMH) after ST-segment elevation myocardial infarction (STEMI) reperfusion increases the risk of major adverse cardiovascular events (MACE). We aimed to integrate a coronary angiography-derived index of microcirculatory resistance (caIMR) with clinical features in a nomogram model for predicting IMH in patients with STEMI following primary percutaneous coronary intervention (PCI). A retrospective study included 309 STEMI patients admitted at Xuzhou Medical University for primary PCI from 2022 to 2023 in training and validation cohorts. Their caIMR was calculated from coronary angiography images and IMH was assessed by cardiac Magnetic Resonance (CMR). A nomogram was constructed through logistic regression analyses. Predictive accuracy, calibration, and clinical usefulness were validated by an area under the curve (AUC) of the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA), respectively. All statistical tests were two-sided. A total of 247 patients were assigned to the training cohort and 62 to the validation cohort randomly. A nomogram was established using two independent predictors of IMH derived from multivariable analysis: caIMR and left ventricular ejection fraction (LVEF). The AUC for the nomogram was 0.844 (95% confidence interval (CI): 0.793–0.896) in the training cohort and 0.834 (95% CI: 0.724–0.944) in the validation cohort. The predicted and actual estimates were significantly correlated in both cohorts, indicating good calibration of the nomogram. The nomogram was clinically useful for the prediction of IMH, within a 10–88% and 10–74% threshold probability in the training and validation cohorts respectively, exhibited by DCA. Furthermore, the nomogram showed superior discriminative ability for MACE prediction compared to CMR-confirmed IMH (AUC 0.726 vs. 0.584, P < 0.001). This novel caIMR-based nomogram resulted in high accuracy of prediction for IMH and MACE in STEMI patients undergoing primary PCI. It may become a convenient tool to predict IMH immediately after the PCI procedure, and help with prognostic judgment and early clinical intervention.
- 7 August 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-12
Open AccessA predictive nomogram for intramyocardial hemorrhage in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention based on coronary angiography-derived index of microcirculatory resistance
Intramyocardial hemorrhage (IMH) after ST-segment elevation myocardial infarction (STEMI) reperfusion increases the risk of major adverse cardiovascular events (MACE). We aimed to integrate a coronary angiography-derived index of microcirculatory resistance (caIMR) with clinical features in a nomogram model for predicting IMH in patients with STEMI following primary percutaneous coronary intervention (PCI). A retrospective study included 309 STEMI patients admitted at Xuzhou Medical University for primary PCI from 2022 to 2023 in training and validation cohorts. Their caIMR was calculated from coronary angiography images and IMH was assessed by cardiac Magnetic Resonance (CMR). A nomogram was constructed through logistic regression analyses. Predictive accuracy, calibration, and clinical usefulness were validated by an area under the curve (AUC) of the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA), respectively. All statistical tests were two-sided. A total of 247 patients were assigned to the training cohort and 62 to the validation cohort randomly. A nomogram was established using two independent predictors of IMH derived from multivariable analysis: caIMR and left ventricular ejection fraction (LVEF). The AUC for the nomogram was 0.844 (95% confidence interval (CI): 0.793–0.896) in the training cohort and 0.834 (95% CI: 0.724–0.944) in the validation cohort. The predicted and actual estimates were significantly correlated in both cohorts, indicating good calibration of the nomogram. The nomogram was clinically useful for the prediction of IMH, within a 10–88% and 10–74% threshold probability in the training and validation cohorts respectively, exhibited by DCA. Furthermore, the nomogram showed superior discriminative ability for MACE prediction compared to CMR-confirmed IMH (AUC 0.726 vs. 0.584, P < 0.001). This novel caIMR-based nomogram resulted in high accuracy of prediction for IMH and MACE in STEMI patients undergoing primary PCI. It may become a convenient tool to predict IMH immediately after the PCI procedure, and help with prognostic judgment and early clinical intervention.
- Open Access
- 14 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Integrating angio-IMR and CMR-assessed microvascular obstruction for improved risk stratification of STEMI patients
Early detection of coronary microvascular dysfunction (CMD) in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI), is challenging. The index of microcirculatory resistance (caIMR), derived from computational pressure-fluid dynamics (CPFD), allows practical assessment of CMD using only routine coronary angiography. However, the prognostic implications of combining caIMR with microvascular obstruction (MVO) identified through cardiac magnetic resonance (CMR) imaging are unclear. This retrospective study investigates the utility of CPFD-caIMR and CMR-derived MVO in predicting major adverse cardiovascular events (MACEs) in 292 STEMI patients who underwent primary PCI, followed by caIMR and CMR evaluations. Patients were stratified into four groups based on caIMR thresholds (≤ 40 U or > 40 U) and the presence/absence of MVO. The primary endpoint was MACEs, defined as cardiac death, recurrent myocardial infarction, target vessel revascularization, or heart failure readmission. Overall, 101/292 patient exhibited discordant caIMR and MVO results. Specifically, 103 patients had caIMR ≤ 40 U without MVO, while 88 patients showed caIMR > 40 U with MVO. Multivariate analysis identified both caIMR > 40 U and MVO as independent predictors of MACEs, with an HR of 3.572 for each unit increase in CPFD-caIMR > 40 U. Combination of CPFD-caIMR and MVO significantly enhanced predictive accuracy. CPFD-caIMR is a reliable, minimally invasive tool for identifying microvascular dysfunction. Combination with CMR-derived MVO improves risk stratification in STEMI patients following PCI, holding promise for the early identification of high-risk patients, enabling targeted and personalized management.
- 14 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessIntegrating angio-IMR and CMR-assessed microvascular obstruction for improved risk stratification of STEMI patients
Early detection of coronary microvascular dysfunction (CMD) in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI), is challenging. The index of microcirculatory resistance (caIMR), derived from computational pressure-fluid dynamics (CPFD), allows practical assessment of CMD using only routine coronary angiography. However, the prognostic implications of combining caIMR with microvascular obstruction (MVO) identified through cardiac magnetic resonance (CMR) imaging are unclear. This retrospective study investigates the utility of CPFD-caIMR and CMR-derived MVO in predicting major adverse cardiovascular events (MACEs) in 292 STEMI patients who underwent primary PCI, followed by caIMR and CMR evaluations. Patients were stratified into four groups based on caIMR thresholds (≤ 40 U or > 40 U) and the presence/absence of MVO. The primary endpoint was MACEs, defined as cardiac death, recurrent myocardial infarction, target vessel revascularization, or heart failure readmission. Overall, 101/292 patient exhibited discordant caIMR and MVO results. Specifically, 103 patients had caIMR ≤ 40 U without MVO, while 88 patients showed caIMR > 40 U with MVO. Multivariate analysis identified both caIMR > 40 U and MVO as independent predictors of MACEs, with an HR of 3.572 for each unit increase in CPFD-caIMR > 40 U. Combination of CPFD-caIMR and MVO significantly enhanced predictive accuracy. CPFD-caIMR is a reliable, minimally invasive tool for identifying microvascular dysfunction. Combination with CMR-derived MVO improves risk stratification in STEMI patients following PCI, holding promise for the early identification of high-risk patients, enabling targeted and personalized management.
- Top Cited PapersOpen Access
- 17 October 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1429133
Gut microbiota and irritable bowel syndrome: status and prospect
Irritable bowel syndrome (IBS) is a very common gastrointestinal disease that, although not as aggressive as tumors, affects patients’ quality of life in different ways. The cause of IBS is still unclear, but more and more studies have shown that the characteristics of the gut microbiota, such as diversity, abundance, and composition, are altered in patients with IBS, compared to the healthy population, which confirms that the gut microbiota plays a crucial role in the development of IBS. This paper aims to identify the commonalities by reviewing a large body of literature. Changes in the characteristics of gut microbiota in patients with different types of IBS are discussed, relevant mechanisms are described, and the treatment modalities of gut microbiota in IBS are summarized. Although there are more clinical trials that have made good progress, more standardized, more generalized, larger-scale, multi-omics clinical studies are what is missing. Overall, gut microbiota plays a crucial role in the development of IBS, and there is even more potential for treating IBS by modulating gut microbiota.
- 17 October 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1429133
Top Cited PapersOpen AccessGut microbiota and irritable bowel syndrome: status and prospect
Irritable bowel syndrome (IBS) is a very common gastrointestinal disease that, although not as aggressive as tumors, affects patients’ quality of life in different ways. The cause of IBS is still unclear, but more and more studies have shown that the characteristics of the gut microbiota, such as diversity, abundance, and composition, are altered in patients with IBS, compared to the healthy population, which confirms that the gut microbiota plays a crucial role in the development of IBS. This paper aims to identify the commonalities by reviewing a large body of literature. Changes in the characteristics of gut microbiota in patients with different types of IBS are discussed, relevant mechanisms are described, and the treatment modalities of gut microbiota in IBS are summarized. Although there are more clinical trials that have made good progress, more standardized, more generalized, larger-scale, multi-omics clinical studies are what is missing. Overall, gut microbiota plays a crucial role in the development of IBS, and there is even more potential for treating IBS by modulating gut microbiota.
- Open Access
- 11 March 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (2) , 423-433
A novel machine learning-derived four-gene signature predicts STEMI and post-STEMI heart failure
High mortality and morbidity rates associated with ST-elevation myocardial infarction (STEMI) and post-STEMI heart failure (HF) necessitate proper risk stratification for coronary artery disease (CAD). A prediction model that combines specificity and convenience is highly required. This study aimed to design a monocyte-based gene assay for predicting STEMI and post-STEMI HF. A total of 1,956 monocyte expression profiles and corresponding clinical data were integrated from multiple sources. Meta-results were obtained through the weighted gene co-expression network analysis (WGCNA) and differential analysis to identify characteristic genes for STEMI. Machine learning models based on the decision tree (DT), support vector machine (SVM), and random forest (RF) algorithms were trained and validated. Five genes overlapped and were subjected to the model proposal. The discriminative performance of the DT model outperformed the other two methods. The established four-gene panel (HLA-J, CFP, STX11, and NFYC) could discriminate STEMI and HF with an area under the curve (AUC) of 0.86 or above. In the gene set enrichment analysis (GSEA), several cardiac pathogenesis pathways and cardiovascular disorder signatures showed statistically significant, concordant differences between subjects with high and low expression levels of the four-gene panel, affirming the validity of the established model. In conclusion, we have developed and validated a model that offers the hope for accurately predicting the risk of STEMI and HF, leading to optimal risk stratification and personalized management of CAD, thereby improving individual outcomes.
- 11 March 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (2) , 423-433
Open AccessA novel machine learning-derived four-gene signature predicts STEMI and post-STEMI heart failure
High mortality and morbidity rates associated with ST-elevation myocardial infarction (STEMI) and post-STEMI heart failure (HF) necessitate proper risk stratification for coronary artery disease (CAD). A prediction model that combines specificity and convenience is highly required. This study aimed to design a monocyte-based gene assay for predicting STEMI and post-STEMI HF. A total of 1,956 monocyte expression profiles and corresponding clinical data were integrated from multiple sources. Meta-results were obtained through the weighted gene co-expression network analysis (WGCNA) and differential analysis to identify characteristic genes for STEMI. Machine learning models based on the decision tree (DT), support vector machine (SVM), and random forest (RF) algorithms were trained and validated. Five genes overlapped and were subjected to the model proposal. The discriminative performance of the DT model outperformed the other two methods. The established four-gene panel (HLA-J, CFP, STX11, and NFYC) could discriminate STEMI and HF with an area under the curve (AUC) of 0.86 or above. In the gene set enrichment analysis (GSEA), several cardiac pathogenesis pathways and cardiovascular disorder signatures showed statistically significant, concordant differences between subjects with high and low expression levels of the four-gene panel, affirming the validity of the established model. In conclusion, we have developed and validated a model that offers the hope for accurately predicting the risk of STEMI and HF, leading to optimal risk stratification and personalized management of CAD, thereby improving individual outcomes.
- Open Access
- 16 February 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230214
Ablação por Cateter para Fibrilação Atrial em Pacientes com Fração de Ejeção do Ventrículo Esquerdo ≤ 45%: Uma Metanálise de Ensaios Clínicos Randomizados
Resumo Fundamento A fibrilação atrial (FA) e a insuficiência cardíaca (IC) coexistem frequentemente, resultando em desfechos adversos. No entanto, permanecem controvérsias quanto à eficácia da ablação por cateter (AC) em pacientes com FA com disfunção ventricular esquerda grave. Objetivos O objetivo deste estudo foi realizar uma metanálise de ensaios prospectivos randomizados e controlados para avaliar a eficácia da AC versus terapia médica (TM) em pacientes com FA com fração de ejeção do ventrículo esquerdo (FEVE) ≤45%. Métodos Procuramos na literatura [...] Resumo Fundamento A fibrilação atrial (FA) e a insuficiência cardíaca (IC) coexistem frequentemente, resultando em desfechos adversos. No entanto, permanecem controvérsias quanto à eficácia da ablação por cateter (AC) em pacientes com FA com disfunção ventricular esquerda grave. Objetivos O objetivo deste estudo foi realizar uma metanálise de ensaios prospectivos randomizados e controlados para avaliar a eficácia da AC versus terapia médica (TM) em pacientes com FA com fração de ejeção do ventrículo esquerdo (FEVE) ≤45%. Métodos Procuramos na literatura
- 16 February 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230214
Open AccessAblação por Cateter para Fibrilação Atrial em Pacientes com Fração de Ejeção do Ventrículo Esquerdo ≤ 45%: Uma Metanálise de Ensaios Clínicos Randomizados
Resumo Fundamento A fibrilação atrial (FA) e a insuficiência cardíaca (IC) coexistem frequentemente, resultando em desfechos adversos. No entanto, permanecem controvérsias quanto à eficácia da ablação por cateter (AC) em pacientes com FA com disfunção ventricular esquerda grave. Objetivos O objetivo deste estudo foi realizar uma metanálise de ensaios prospectivos randomizados e controlados para avaliar a eficácia da AC versus terapia médica (TM) em pacientes com FA com fração de ejeção do ventrículo esquerdo (FEVE) ≤45%. Métodos Procuramos na literatura [...] Resumo Fundamento A fibrilação atrial (FA) e a insuficiência cardíaca (IC) coexistem frequentemente, resultando em desfechos adversos. No entanto, permanecem controvérsias quanto à eficácia da ablação por cateter (AC) em pacientes com FA com disfunção ventricular esquerda grave. Objetivos O objetivo deste estudo foi realizar uma metanálise de ensaios prospectivos randomizados e controlados para avaliar a eficácia da AC versus terapia médica (TM) em pacientes com FA com fração de ejeção do ventrículo esquerdo (FEVE) ≤45%. Métodos Procuramos na literatura